lunedì, 26 luglio 2021
7 Dicembre 2017

FDA Grants Priority Review to Maintenance Rucaparib for Ovarian Cancer

December 6, 2017 – The FDA has granted a priority review to a supplemental new drug application (sNDA) for rucaparib for use as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the manufacturer of the PARP inhibitor. The sNDA is based on findings from the phase III ARIEL3 trial, in which maintenance … (leggi tutto)